March 28, 2025 08:00 AM EDT

BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer

Elizabeth Cairns

Senior biopharma journalist

BioNTech has highly encouraging survival data for its bispecific antibody combining checkpoint blockade with VEGF-A inhibition as a first-line treatment for a serious form of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

FDA's Peter Marks resigns, saying he won't accept Kennedy's 'misinformation and lies'

Bluebird gets new M&A bid, seeking to top private equity offer

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic

Vertex’s second-generation diabetes cell therapy fails early-stage study

Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B

European regulator rejects Lilly's Alzheimer’s drug over potentially fatal side effects

BioN­Tech de­tails promis­ing mid-stage da­ta for its PD-L1xVEGF in ag­gres­sive lung can­cer

Senior biopharma journalist

Sign up to read this article for free.

more like this

Gondolabio

Palo Alto, CA, USA

BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer